Recipharm Appoints Prof. Hans Lennernäs to one of its operating Boards

5th February 2013: Recipharm Pharmaceutical Development AB is pleased to announce the appointment of Dr Hans Lennernäs to the company's Board of Directors.

Dr. Hans Lennernäs is a Professor of Biopharmaceutics at Uppsala University. He currently manages  an IMI project entitled OrBiTo, which aims to improve oral drug delivery;   controlling a budget  of 24.5 MEuro   His research responsibilities and remit  are focused on membrane transport and metabolism of drugs/metabolites in the gastrointestinal tract, hepatobiliary system and cancer tissues.

Dr. Lennernäs has served as  the Principal Investigator in an extensive collaboration with the Food Drug & Administration, USA, University of Michigan, USA, and Medical Product Agency, Sweden over the course of  several years in which he developed a new guideline for the Biopharmaceutics Classification System. He has established an extensive and widely used human permeability database.

In addition to his academic achievements, Dr Lennernäs  has built an entrepreneurial reputation  by cofounding  several companies including DuoCort Pharma AB, and LIDDS AB, whilst investing in a number of patents.

"I am very much looking forward to serving  on the Board of Directors at Recipharm Pharmaceutical Development AB. Indeed, this is  a company with an excellent track record and  an impressive  long term strategy in place", Hans Lennernäs commented.

"We are very pleased to welcome a Board Member of Hans Lennernäs calibre", remarked General Manager Maria Lundberg. "His track record of successfully inventing and developing several novel drug delivery systems that are currently in pre-clinical phase and in preparation for phase I, II and III clinical trials, makes him an excellent addition to the Board.  I look forward to Recipharm benefiting from his Board level contribution and insights that will help the company perpetuate its track record of commercial success".

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 203 6740  or e-mail: [email protected] 

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.